L.A. Feedback

Quote

Anonymous

Guest
Very nice and considerate interviewers.

HR & Mgrs to convene to review interview performance, rep experience and achievements, number of therapeutic categories that intersect with Actavis portfolio. Then the results from background checks before offers are extended mid November.

Deep pool of well qualified candidates given all the industry layoffs. Likely leaning towards reps under the $85 k cap as those with a higher salary history would likely jump ship as soon as a higher paying opportunity comes along.

Above average compensation with an up and coming company which should translate into stability vs big pharma annual rounds of headcount reductions.
 

25 R&D product entities.

That's better than a lot of big pharma companies.

Have to wonder if any of these compounds and biosimilars pan out if Actavis gets a hungry wolf like Pfizer lurking around the door ready to pounce.
 
I would agree with the original poster. I thought the check in people seemed a bit frazzled and grumpy. But the 2 interviewers were great. I was told by the recruiter that they were sending only 2 people for each projected territory. Has anyone else heard this?
 
I went to the f2f interviews. I do not have experience in any of the therapeutic areas so will they even consider people who do not or was I a fill in? I have 10 plus years experience
 
If there is more than one position per city, I.e. one for each of the core brand therapeutic categories, it could explain why there are lots of candidates from one city.
 
Anonymous said:
I went to the f2f interviews. I do not have experience in any of the therapeutic areas so will they even consider people who do not or was I a fill in? I have 10 plus years experience
Click to expand...

You would not have been invited if you weren't seriously being considered. The interviewers don't need interview practice. They are interfacing with talent and prospective new hires.

If you had a f2f you are in the running!
 
http://www.businessweek.com/ap/2013-10-29/drugmaker-actavis-3q-profit-falls-forecast-climbs

http://online.wsj.com/article/BT-CO-20131029-709989.html

http://blogs.wsj.com/moneybeat/2013/10/29/auto-draft-9/

http://www.cnbc.com/id/101152928

http://www.nasdaq.com/article/actav...ull-year-outlook---quick-facts-20131029-00655

http://markets.ft.com/research/Markets/Tearsheets/Forecasts?s=ACT:NYQ

http://finance.yahoo.com/news/drugmaker-actavis-3q-profit-falls-174217964.html

http://www.fool.com/investing/gener...u-keep-buying-these-beneficiaries-of-the.aspx

"Clearly, we are seeing a paradigm shift, one that is bad for large pharma but good for generic drug companies, pharmacies, and most importantly, consumers!

With Actavis, despite its large gains, it still trades at just 12.3 times next year's earnings, making it very cheap with a boatload of catalysts in the next few years. Given the strong performance of its quarter, its valuation, and its increased guidance, I think it's hard not to be bullish long term."

http://www.actavis.com.mt/en/news/Actavis+named+to+Fortune+500.htm

http://investorplace.com/2013/10/generic-drugmaker-debt-ceiling-actavis/#.UnQ-wFNckg4

http://www.timesofmalta.com/article...-bolstered-by-acquisition.491916#.UnQ_IVNckg4

If called, I'm ALL In!
 


Write your reply...
Top Bottom
Back
Quote